Payment overview · 2025
General Payments
$247.61
11 reported records · 8 companies
Healthcare provider profile · identity verified
Mary Joenborg
Allopathic & Osteopathic Physicians|Family Medicine · MOUNT VERNON, KY · NPI 1437680964
Verified facts
What the public records show
CMS Open Payments records show Mary Joenborg received $247.61 in general payments during 2025 across 11 reported records.
Novartis Pharmaceuticals Corporation accounted for 38.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Farxiga, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $96.30 | 38.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.04 | 12.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.05 | 10.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.69 | 8.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.19 | 7.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.48 | 7.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.00 | 7.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.86 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $247.61 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $96.30 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 28 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
72 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 19 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
28 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
140 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 579 | 155 |
| Atorvastatin Calcium | Atorvastatin Calcium | 578 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 537 | 149 |
| Montelukast Sodium | Montelukast Sodium | 530 | 159 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 485 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 480 | 141 |
| Gabapentin | Gabapentin | 472 | 72 |
| Omeprazole | Omeprazole | 392 | 104 |
| Metoprolol Succinate | Metoprolol Succinate | 321 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 294 | 93 |
| Furosemide | Furosemide | 287 | 86 |
| Losartan Potassium | Losartan Potassium | 287 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 73 |
| Fluticasone Propionate | Fluticasone Propionate | 232 | 108 |
| Metformin Hcl | Metformin Hcl | 207 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 202 | 53 |
| Pregabalin | Pregabalin | 198 | 29 |
| Potassium Chloride | Potassium Chloride | 197 | 60 |
| Ozempic | Semaglutide | 195 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 189 | 58 |
| Tramadol Hcl | Tramadol Hcl | 182 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 181 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 71 |
| Simvastatin | Simvastatin | 174 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 173 | 53 |
| Carvedilol | Carvedilol | 172 | 53 |
| Lorazepam | Lorazepam | 163 | 27 |
| Meloxicam | Meloxicam | 162 | 62 |
| Clonazepam | Clonazepam | 150 | 25 |
| Januvia | Sitagliptin Phosphate | 148 | 29 |
| Famotidine | Famotidine | 147 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 52 |
| Prednisone | Prednisone | 142 | 72 |
| Eliquis | Apixaban | 140 | 36 |
| Sertraline Hcl | Sertraline Hcl | 140 | 39 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 132 | 34 |
| Mounjaro | Tirzepatide | 124 | 24 |
| Clonidine Hcl | Clonidine Hcl | 122 | 42 |
| Fenofibrate | Fenofibrate Nanocrystallized | 116 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 36 |
| Trazodone Hcl | Trazodone Hcl | 113 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 111 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 102 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 95 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 94 | 30 |
| Jardiance | Empagliflozin | 94 | 32 |
| Ondansetron Odt | Ondansetron | 94 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 94 | 24 |
| Diazepam | Diazepam | 91 | 17 |
| Irbesartan | Irbesartan | 89 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 48 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 24 |
| Alendronate Sodium | Alendronate Sodium | 80 | 30 |
| Allopurinol | Allopurinol | 79 | 22 |
| Ibuprofen | Ibuprofen | 79 | 35 |
| Alprazolam | Alprazolam | 78 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 39 |
| Doxepin Hcl | Doxepin Hcl | 77 | 21 |
| Ezetimibe | Ezetimibe | 76 | 22 |
| Xarelto | Rivaroxaban | 75 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | 31 |
| Linzess | Linaclotide | 72 | 22 |
| Synthroid | Levothyroxine Sodium | 72 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 19 |
| Nifedipine Er | Nifedipine | 68 | 25 |
| Nystatin | Nystatin | 68 | 30 |
| Finasteride | Finasteride | 64 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 64 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 13 |
| Spironolactone | Spironolactone | 61 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 35 |
| Metformin Hcl Er | Metformin Hcl | 60 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 22 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 59 | 17 |
| Lansoprazole | Lansoprazole | 58 | 14 |
| Farxiga | Dapagliflozin Propanediol | 56 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 56 | 21 |
| Fluconazole | Fluconazole | 55 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 42 |
| Glipizide Er | Glipizide | 53 | 11 |
| Methocarbamol | Methocarbamol | 53 | 24 |
| Topiramate | Topiramate | 51 | suppressed |
| Atenolol | Atenolol | 50 | 13 |
| Ramipril | Ramipril | 50 | 12 |
| Bupropion Xl | Bupropion Hcl | 48 | 19 |
| Estradiol | Estradiol | 48 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 48 | 14 |
| Sucralfate | Sucralfate | 48 | 15 |
| Temazepam | Temazepam | 48 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 47 | 20 |
| Mirtazapine | Mirtazapine | 46 | 11 |
| Buspirone Hcl | Buspirone Hcl | 45 | 23 |
| Glipizide | Glipizide | 45 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 17 |
| Meclizine Hcl | Meclizine Hcl | 44 | 20 |
| Rexulti | Brexpiprazole | 43 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 12 |
| Valsartan | Valsartan | 42 | suppressed |
| Nitroglycerin | Nitroglycerin | 41 | 20 |
| Spiriva Respimat | Tiotropium Bromide | 40 | 14 |
| Bumetanide | Bumetanide | 39 | 15 |
| Spiriva Handihaler | Tiotropium Bromide | 38 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 38 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | suppressed |
| Celecoxib | Celecoxib | 36 | suppressed |
| Azithromycin | Azithromycin | 34 | 18 |
| Donepezil Hcl | Donepezil Hcl | 34 | 15 |
| Dutasteride | Dutasteride | 34 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 18 |
| Primidone | Primidone | 32 | suppressed |
| Myrbetriq | Mirabegron | 30 | 12 |
| Propranolol Hcl | Propranolol Hcl | 30 | 12 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Colchicine | Colchicine | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 12 |
| Mupirocin | Mupirocin | 29 | 15 |
| Promethazine Hcl | Promethazine Hcl | 29 | 13 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 26 |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 23 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Cefdinir | Cefdinir | 23 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 19 |
| Metolazone | Metolazone | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 18 |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Azstarys | Serdexmethylphen/Dexmethylphen | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $247.61 · 11 records | Novartis Pharmaceuticals Corporation | ABRYSVO, AREXVY, CAPLYTA, COMIRNATY, FARXIGA, Kerendia, LEQVIO, PREVNAR 20, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error